Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Eur J Heart Fail. 2023 Apr 23;25(5):632–641. doi: 10.1002/ejhf.2853

Figure 1:

Figure 1:

Win Ratio in EMPULSE trial (unstratified+): all paired comparisons of empagliflozin and placebo: 265 × 265 pairs.

The Win Ratio in EMPULSE trial (unstratified): Figure 1 shows the distribution of wins and ties for each of the 70,225 (265 × 265 pairs) empagliflozin versus placebo paired comparisons at each level of the hierarchy of the primary composite endpoint. Note that the primary analysis in EMPULSE was a stratified win ratio. HF = heart failure; KCCQ-TSS = Kansas City Cardiomyopathy Questionnaire Total Symptom Score.